缺氧诱导转录因子:肿瘤发生的设计师和抗癌药物发现的目标。

IF 3.6 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY Transcription-Austin Pub Date : 2024-10-29 DOI:10.1080/21541264.2024.2417475
Ali Tavassoli, Alexander McDermott
{"title":"缺氧诱导转录因子:肿瘤发生的设计师和抗癌药物发现的目标。","authors":"Ali Tavassoli, Alexander McDermott","doi":"10.1080/21541264.2024.2417475","DOIUrl":null,"url":null,"abstract":"<p><p>Hypoxia-inducible factors (HIFs) play a pivotal role as master regulators of tumor survival and growth, controlling a wide array of cellular processes in response to hypoxic stress. Clinical data correlates upregulated HIF-1 and HIF-2 levels with an aggressive tumor phenotype and poor patient outcome. Despite extensive validation as a target in cancer, pharmaceutical targeting of HIFs, particularly the interaction between α and βsubunits that forms the active transcription factor, has proved challenging. Nonetheless, many indirect inhibitors of HIFs have been identified, targeting diverse parts of this pathway. Significant strides have also been made in the development of direct inhibitors of HIF-2, exemplified by the FDA approval of Belzutifan for the treatment of metastatic clear cell renal carcinoma. While efforts to target HIF-1 using various therapeutic modalities have shown promise, no clinical candidates have yet emerged. This review aims to provide insights into the intricate and extensive role played by HIFs in cancer, and the ongoing efforts to develop therapeutic agents against this target.</p>","PeriodicalId":47009,"journal":{"name":"Transcription-Austin","volume":null,"pages":null},"PeriodicalIF":3.6000,"publicationDate":"2024-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Hypoxia-inducing transcription factors: architects of tumorigenesis and targets for anticancer drug discovery.\",\"authors\":\"Ali Tavassoli, Alexander McDermott\",\"doi\":\"10.1080/21541264.2024.2417475\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Hypoxia-inducible factors (HIFs) play a pivotal role as master regulators of tumor survival and growth, controlling a wide array of cellular processes in response to hypoxic stress. Clinical data correlates upregulated HIF-1 and HIF-2 levels with an aggressive tumor phenotype and poor patient outcome. Despite extensive validation as a target in cancer, pharmaceutical targeting of HIFs, particularly the interaction between α and βsubunits that forms the active transcription factor, has proved challenging. Nonetheless, many indirect inhibitors of HIFs have been identified, targeting diverse parts of this pathway. Significant strides have also been made in the development of direct inhibitors of HIF-2, exemplified by the FDA approval of Belzutifan for the treatment of metastatic clear cell renal carcinoma. While efforts to target HIF-1 using various therapeutic modalities have shown promise, no clinical candidates have yet emerged. This review aims to provide insights into the intricate and extensive role played by HIFs in cancer, and the ongoing efforts to develop therapeutic agents against this target.</p>\",\"PeriodicalId\":47009,\"journal\":{\"name\":\"Transcription-Austin\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":3.6000,\"publicationDate\":\"2024-10-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Transcription-Austin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/21541264.2024.2417475\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transcription-Austin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/21541264.2024.2417475","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

缺氧诱导因子(HIFs)作为肿瘤存活和生长的主调控因子发挥着举足轻重的作用,在缺氧压力下控制着一系列细胞过程。临床数据表明,HIF-1 和 HIF-2 水平的上调与侵袭性肿瘤表型和患者预后不良有关。尽管 HIFs 作为癌症靶点已得到广泛验证,但药物靶向 HIFs,特别是形成活性转录因子的 α 和 β 亚基之间的相互作用,仍具有挑战性。尽管如此,许多针对这一途径不同部分的 HIFs 间接抑制剂已被发现。在开发 HIF-2 直接抑制剂方面也取得了重大进展,例如美国食品及药物管理局批准贝珠替凡用于治疗转移性透明细胞肾癌。虽然利用各种治疗方法靶向 HIF-1 的努力已显示出前景,但尚未出现临床候选药物。本综述旨在深入探讨 HIFs 在癌症中发挥的复杂而广泛的作用,以及目前针对这一靶点开发治疗药物的努力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Hypoxia-inducing transcription factors: architects of tumorigenesis and targets for anticancer drug discovery.

Hypoxia-inducible factors (HIFs) play a pivotal role as master regulators of tumor survival and growth, controlling a wide array of cellular processes in response to hypoxic stress. Clinical data correlates upregulated HIF-1 and HIF-2 levels with an aggressive tumor phenotype and poor patient outcome. Despite extensive validation as a target in cancer, pharmaceutical targeting of HIFs, particularly the interaction between α and βsubunits that forms the active transcription factor, has proved challenging. Nonetheless, many indirect inhibitors of HIFs have been identified, targeting diverse parts of this pathway. Significant strides have also been made in the development of direct inhibitors of HIF-2, exemplified by the FDA approval of Belzutifan for the treatment of metastatic clear cell renal carcinoma. While efforts to target HIF-1 using various therapeutic modalities have shown promise, no clinical candidates have yet emerged. This review aims to provide insights into the intricate and extensive role played by HIFs in cancer, and the ongoing efforts to develop therapeutic agents against this target.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Transcription-Austin
Transcription-Austin BIOCHEMISTRY & MOLECULAR BIOLOGY-
CiteScore
6.50
自引率
5.60%
发文量
9
期刊最新文献
Hypoxia-inducing transcription factors: architects of tumorigenesis and targets for anticancer drug discovery. From silence to symphony: transcriptional repression and recovery in response to DNA damage. Structure and function of bacterial transcription regulators of the SorC family. Deciphering the dynamic code: DNA recognition by transcription factors in the ever-changing genome. Negative feedback systems for modelling NF-κB transcription factor oscillatory activity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1